CN1263757C - 特异于腺苷a1,a2a和a3受体的化合物及其应用 - Google Patents
特异于腺苷a1,a2a和a3受体的化合物及其应用 Download PDFInfo
- Publication number
- CN1263757C CN1263757C CNB018224601A CN01822460A CN1263757C CN 1263757 C CN1263757 C CN 1263757C CN B018224601 A CNB018224601 A CN B018224601A CN 01822460 A CN01822460 A CN 01822460A CN 1263757 C CN1263757 C CN 1263757C
- Authority
- CN
- China
- Prior art keywords
- compound
- disease
- treatment
- amino
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/728,316 | 2000-12-01 | ||
US09/728,607 | 2000-12-01 | ||
US09/728,616 US7160890B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A3 receptor and uses thereof |
US09/728,316 US6680322B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A1 receptors and uses thereof |
US09/728,616 | 2000-12-01 | ||
US09/728,607 US6664252B2 (en) | 1999-12-02 | 2000-12-01 | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1489590A CN1489590A (zh) | 2004-04-14 |
CN1263757C true CN1263757C (zh) | 2006-07-12 |
Family
ID=27419112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018224601A Expired - Fee Related CN1263757C (zh) | 2000-12-01 | 2001-11-30 | 特异于腺苷a1,a2a和a3受体的化合物及其应用 |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1347980A4 (de) |
JP (1) | JP4579497B2 (de) |
CN (1) | CN1263757C (de) |
AP (1) | AP1893A (de) |
AU (1) | AU2002248151B2 (de) |
BR (1) | BR0115847A (de) |
CA (1) | CA2430577A1 (de) |
CZ (1) | CZ20031831A3 (de) |
EA (1) | EA007254B1 (de) |
HU (1) | HUP0400692A3 (de) |
IL (1) | IL155962A0 (de) |
ME (1) | MEP35308A (de) |
MX (1) | MXPA03004717A (de) |
NO (1) | NO327207B1 (de) |
NZ (1) | NZ525885A (de) |
OA (1) | OA13295A (de) |
PL (1) | PL363245A1 (de) |
WO (1) | WO2002057267A1 (de) |
YU (1) | YU42703A (de) |
ZA (1) | ZA200303729B (de) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104350056A (zh) * | 2012-06-07 | 2015-02-11 | 霍夫曼-拉罗奇有限公司 | 端锚聚合酶的吡咯并嘧啶酮和吡咯并吡啶酮抑制剂 |
CN105473581A (zh) * | 2013-06-21 | 2016-04-06 | 齐尼思表观遗传学公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
US10010556B2 (en) | 2013-06-21 | 2018-07-03 | Zenith Epigenetics Ltd. | Bicyclic bromodomain inhibitors |
US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
CN110128316A (zh) * | 2019-05-22 | 2019-08-16 | 北京大学深圳研究生院 | 5位取代的β-脯氨酸及其衍生物的制备方法 |
US10500209B2 (en) | 2013-07-31 | 2019-12-10 | Zenith Epigenetics Ltd. | Quinazolinones as bromodomain inhibitors |
US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5090531A (en) * | 1990-01-10 | 1992-02-25 | Lord Corporation | Electrophoretic fluid differential |
CZ302486B6 (cs) | 1998-06-02 | 2011-06-15 | Osi Pharmaceuticals, Inc. | N-6-Substituovaný 7-deazapurin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
DE10148883A1 (de) * | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | Pyrimidinderivate |
EP1450811B1 (de) * | 2001-11-30 | 2009-10-21 | OSI Pharmaceuticals, Inc. | Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen |
CA2469316A1 (en) * | 2001-12-07 | 2003-06-19 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as gsk-3 inhibitors |
EA011809B1 (ru) | 2001-12-20 | 2009-06-30 | Оси Фармасьютикалз, Инк. | Пиримидиновые соединения, их применение в качестве a-селективных антагонистов и способ их получения |
CN1816551A (zh) | 2001-12-20 | 2006-08-09 | Osi药物公司 | 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途 |
CA2502429A1 (en) * | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
EP3421471B1 (de) | 2006-04-25 | 2021-05-26 | Astex Therapeutics Limited | Purin- und deazapurinderivate als pharmazeutische verbindungen |
US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
TW200808819A (en) * | 2006-06-19 | 2008-02-16 | Solvay Pharm Gmbh | Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty |
WO2009047563A1 (en) | 2007-10-11 | 2009-04-16 | Astrazeneca Ab | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
EP2247596A2 (de) | 2008-01-11 | 2010-11-10 | Natco Pharma Limited | Neuartige pyrazol-[3,4-d-]pyrimidin-derivate als wirkstoffe gegen krebs |
SI2694056T1 (sl) | 2011-04-01 | 2019-12-31 | Astrazeneca Ab | Terapevtsko zdravljenje |
DK2785349T4 (da) | 2011-11-30 | 2023-01-09 | Astrazeneca Ab | Kombinationsbehandling af cancer |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
CN108349977B (zh) * | 2015-01-20 | 2021-05-25 | 无锡福祈制药有限公司 | Jak抑制剂 |
KR102006684B1 (ko) | 2015-04-29 | 2019-08-02 | 우시 포춘 파마슈티컬 컴퍼니 리미티드 | Jak 억제제 |
CA2983481C (en) | 2015-05-29 | 2020-04-14 | Wuxi Fortune Pharmaceutical Co., Ltd | Janus kinase inhibitor |
CN105771672B (zh) * | 2016-04-18 | 2018-03-02 | 天津工业大学 | 一种抗污染抗菌芳香聚酰胺反渗透复合膜及制备方法 |
CN108570054B (zh) * | 2017-03-07 | 2021-07-16 | 广州再极医药科技有限公司 | 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用 |
CN108017584B (zh) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3腺苷受体的小分子拮抗剂 |
KR20210033444A (ko) * | 2018-06-04 | 2021-03-26 | 엑스사이언티아 엘티디 | 아데노신 수용체 길항제로서 피라졸로피리미딘 화합물 |
CN110272373B (zh) * | 2019-07-02 | 2022-07-29 | 天津国际生物医药联合研究院 | 一种具有选择性的腺苷a1受体拮抗剂及其应用 |
CN114085178A (zh) * | 2021-12-29 | 2022-02-25 | 苏州楚凯药业有限公司 | 一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2895961B2 (ja) * | 1992-12-17 | 1999-05-31 | フアイザー・インコーポレイテツド | Crfアンタゴニストとしてのピロロピリミジン |
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
CZ302486B6 (cs) * | 1998-06-02 | 2011-06-15 | Osi Pharmaceuticals, Inc. | N-6-Substituovaný 7-deazapurin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem |
KR100840727B1 (ko) * | 1999-12-02 | 2008-06-23 | 오에스아이 파마슈티컬스, 인코포레이티드 | 아데노신 a1, a2a 및 a3 수용체 특이 화합물 및 그의 사용방법 |
EP1450811B1 (de) * | 2001-11-30 | 2009-10-21 | OSI Pharmaceuticals, Inc. | Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen |
-
2001
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/pt not_active Application Discontinuation
- 2001-11-30 YU YU42703A patent/YU42703A/sh unknown
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/ja not_active Expired - Fee Related
- 2001-11-30 IL IL15596201A patent/IL155962A0/xx unknown
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/hu unknown
- 2001-11-30 EA EA200300628A patent/EA007254B1/ru not_active IP Right Cessation
- 2001-11-30 PL PL01363245A patent/PL363245A1/xx not_active Application Discontinuation
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/cs unknown
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/xx unknown
- 2001-11-30 CN CNB018224601A patent/CN1263757C/zh not_active Expired - Fee Related
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/es active IP Right Grant
- 2001-11-30 EP EP01997029A patent/EP1347980A4/de not_active Ceased
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en active IP Right Grant
-
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/no not_active IP Right Cessation
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104350056A (zh) * | 2012-06-07 | 2015-02-11 | 霍夫曼-拉罗奇有限公司 | 端锚聚合酶的吡咯并嘧啶酮和吡咯并吡啶酮抑制剂 |
CN105473581B (zh) * | 2013-06-21 | 2019-04-23 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
US10010556B2 (en) | 2013-06-21 | 2018-07-03 | Zenith Epigenetics Ltd. | Bicyclic bromodomain inhibitors |
US10363257B2 (en) | 2013-06-21 | 2019-07-30 | Zenith Epigenetics Ltd. | Bicyclic bromodomain inhibitors |
US11026926B2 (en) | 2013-06-21 | 2021-06-08 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
US10772892B2 (en) | 2013-06-21 | 2020-09-15 | Zenith Epigenetics Ltd. | Bicyclic bromodomain inhibitors |
US10226451B2 (en) | 2013-06-21 | 2019-03-12 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
CN105492439B (zh) * | 2013-06-21 | 2019-11-22 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的取代的双环化合物 |
CN105473581A (zh) * | 2013-06-21 | 2016-04-06 | 齐尼思表观遗传学公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
US11446306B2 (en) | 2013-06-21 | 2022-09-20 | Zenith Epigenetics Ltd. | Bicyclic bromodomain inhibitors |
CN105492439A (zh) * | 2013-06-21 | 2016-04-13 | 齐尼思表观遗传学公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
US10166215B2 (en) | 2013-06-21 | 2019-01-01 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
US10500209B2 (en) | 2013-07-31 | 2019-12-10 | Zenith Epigenetics Ltd. | Quinazolinones as bromodomain inhibitors |
US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
CN110128316A (zh) * | 2019-05-22 | 2019-08-16 | 北京大学深圳研究生院 | 5位取代的β-脯氨酸及其衍生物的制备方法 |
CN110128316B (zh) * | 2019-05-22 | 2021-08-31 | 北京大学深圳研究生院 | 5位取代的β-脯氨酸及其衍生物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP4579497B2 (ja) | 2010-11-10 |
EP1347980A4 (de) | 2005-02-09 |
ZA200303729B (en) | 2004-05-14 |
MEP35308A (en) | 2011-02-10 |
NO327207B1 (no) | 2009-05-11 |
YU42703A (sh) | 2006-03-03 |
OA13295A (en) | 2007-04-13 |
CN1489590A (zh) | 2004-04-14 |
CZ20031831A3 (cs) | 2004-05-12 |
NO20032482D0 (no) | 2003-06-02 |
MXPA03004717A (es) | 2004-06-30 |
AU2002248151B2 (en) | 2008-02-21 |
CA2430577A1 (en) | 2002-07-25 |
BR0115847A (pt) | 2004-02-25 |
NZ525885A (en) | 2005-01-28 |
NO20032482L (no) | 2003-07-28 |
HUP0400692A3 (en) | 2007-09-28 |
IL155962A0 (en) | 2003-12-23 |
EA007254B1 (ru) | 2006-08-25 |
EA200300628A1 (ru) | 2003-12-25 |
AP2003002807A0 (en) | 2003-06-30 |
EP1347980A1 (de) | 2003-10-01 |
WO2002057267A1 (en) | 2002-07-25 |
AP1893A (en) | 2008-09-23 |
PL363245A1 (en) | 2004-11-15 |
JP2004517896A (ja) | 2004-06-17 |
HUP0400692A2 (hu) | 2004-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1263757C (zh) | 特异于腺苷a1,a2a和a3受体的化合物及其应用 | |
KR100722194B1 (ko) | 피롤로[2,3디]피리미딘 조성물 및 이의 용도 | |
US6680324B2 (en) | Compounds specific to adenosine A1 receptors and uses thereof | |
US6680322B2 (en) | Compounds specific to adenosine A1 receptors and uses thereof | |
US6673802B2 (en) | Compounds specific to adenosine A3 receptor and uses thereof | |
US7160890B2 (en) | Compounds specific to adenosine A3 receptor and uses thereof | |
US6664252B2 (en) | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof | |
US20090192177A1 (en) | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | |
CN1434807A (zh) | 糖元合成酶激酶3的基于吡嗪的抑制剂 | |
CN1701074A (zh) | 用作依赖细胞周期蛋白激酶抑制剂的吡唑并嘧啶 | |
CN1882591A (zh) | 具有PDE-5抑制活性的5,7-二氨基吡唑并[4,3-d]嘧啶 | |
CN1853723A (zh) | 采用MDM2:p53相互作用的小分子抑制剂的联合治疗 | |
CN1894234A (zh) | 二肽基肽酶抑制剂 | |
EP1731520A1 (de) | Pyrrolo[2,3-d]pyrimidin-Derivate als Antagonisten von Adenosin A1, A2A und A3 | |
US6686366B1 (en) | Compounds specific to adenosine A3 receptor and uses thereof | |
CN1816551A (zh) | 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途 | |
CN1735614A (zh) | 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶 | |
US6878716B1 (en) | Compounds specific to adenosine A1 receptor and uses thereof | |
CN1993362A (zh) | 稠合的杂环化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060712 Termination date: 20111130 |